Clinical Trial Update: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing KSI-301 with Aflibercept in diabetic macular edema was terminated, with results posted on 2024-08-22.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)
• KSI-301 (KSI-301)

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Diabetic Macular Edema | Phase 3 | Status: TERMINATED | Results posted: 2024-08-22